Desulfovibrio confers resilience to the comorbidity of pain and anxiety in a mouse model of chronic inflammatory pain.
Anxiety
Comorbidity
Desulfovibrio
Diazepam
Pain
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
03
10
2022
accepted:
04
11
2022
pubmed:
29
11
2022
medline:
10
1
2023
entrez:
28
11
2022
Statut:
ppublish
Résumé
Patients with chronic pain frequently suffer from anxiety symptoms. It has been well established that gut microbiota is associated with the pathogenesis of pain and anxiety. However, it is unknown whether the gut microbiota, particularly the specific bacteria, play a role in the comorbidity of chronic pain and anxiety. Chronic inflammatory pain was induced in mice by a single injection of complete Freund's adjuvant (CFA). Mice were then separated into anxiety-susceptible and anxiety-resilient phenotypes by hierarchical clustering analysis of behaviors. Fecal samples were collected to perform 16S rRNA gene sequencing. Chronic diazepam intervention served as a therapeutic strategy and its effect on the composition of gut microbiota was also determined. α-Diversity and β-diversity both showed significant differences among the groups. A total of 12 gut bacteria were both altered after CFA injection and reversed by chronic diazepam treatment. More importantly, the pain hypersensitivity and anxiety-like behaviors were relieved by chronic diazepam treatment. Interestingly, we also found that Desulfovibrio was increased in anxiety-resilient group compared to control and anxiety-susceptible groups. Abnormal composition of gut microbiota plays an essential role in chronic pain as well as in anxiety. Besides, the increased level of Desulfovibrio in anxiety-resilient mice indicated its therapeutic effects on the comorbidity of pain and anxiety. Collectively, targeting gut microbiota, especially increasing the Desulfovibrio level, might be effective in the alleviation of chronic pain-anxiety comorbidity.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with chronic pain frequently suffer from anxiety symptoms. It has been well established that gut microbiota is associated with the pathogenesis of pain and anxiety. However, it is unknown whether the gut microbiota, particularly the specific bacteria, play a role in the comorbidity of chronic pain and anxiety.
METHODS
METHODS
Chronic inflammatory pain was induced in mice by a single injection of complete Freund's adjuvant (CFA). Mice were then separated into anxiety-susceptible and anxiety-resilient phenotypes by hierarchical clustering analysis of behaviors. Fecal samples were collected to perform 16S rRNA gene sequencing. Chronic diazepam intervention served as a therapeutic strategy and its effect on the composition of gut microbiota was also determined.
RESULTS
RESULTS
α-Diversity and β-diversity both showed significant differences among the groups. A total of 12 gut bacteria were both altered after CFA injection and reversed by chronic diazepam treatment. More importantly, the pain hypersensitivity and anxiety-like behaviors were relieved by chronic diazepam treatment. Interestingly, we also found that Desulfovibrio was increased in anxiety-resilient group compared to control and anxiety-susceptible groups.
CONCLUSION
CONCLUSIONS
Abnormal composition of gut microbiota plays an essential role in chronic pain as well as in anxiety. Besides, the increased level of Desulfovibrio in anxiety-resilient mice indicated its therapeutic effects on the comorbidity of pain and anxiety. Collectively, targeting gut microbiota, especially increasing the Desulfovibrio level, might be effective in the alleviation of chronic pain-anxiety comorbidity.
Identifiants
pubmed: 36441221
doi: 10.1007/s00213-022-06277-4
pii: 10.1007/s00213-022-06277-4
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Diazepam
Q3JTX2Q7TU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
87-100Subventions
Organisme : National Natural Science Foundation of China
ID : 82271254
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Amaral FA, Sachs D, Costa VV, Fagundes CT, Cisalpino D, Cunha TM et al (2008) Commensal microbiota is fundamental for the development of inflammatory pain. Proc Natl Acad Sci U S A 105:2193–2197
doi: 10.1073/pnas.0711891105
Basbaum AI, Bautista DM, Scherrer G, Julius D (2009) Cellular and molecular mechanisms of pain. Cell 139:267–284
doi: 10.1016/j.cell.2009.09.028
Belkaid Y, Hand TW (2014) Role of the microbiota in immunity and inflammation. Cell 157:121–141
doi: 10.1016/j.cell.2014.03.011
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55–63
doi: 10.1016/0165-0270(94)90144-9
Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S (2021) Short chain fatty acids and its producing organisms: an overlooked therapy for IBD? EBioMedicine 66:103293
doi: 10.1016/j.ebiom.2021.103293
Dixon WJ (1980) Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20:441–462
doi: 10.1146/annurev.pa.20.040180.002301
Dominguez-Bello MG, Godoy-Vitorino F, Knight R, Blaser MJ (2019) Role of the microbiome in human development. Gut 68:1108–1114
doi: 10.1136/gutjnl-2018-317503
Emoto T, Hayashi T, Tabata T, Yamashita T, Watanabe H, Takahashi T et al (2021) Metagenomic analysis of gut microbiota reveals its role in trimethylamine metabolism in heart failure. Int J Cardiol 338:138–142
doi: 10.1016/j.ijcard.2021.06.003
Guida F, Boccella S, Belardo C, Iannotta M, Piscitelli F, De Filippis F et al (2020) Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain. Brain Behav Immun 85:128–141
doi: 10.1016/j.bbi.2019.04.006
Guo R, Chen LH, Xing C, Liu T (2019) Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. Br J Anaesth 123:637–654
doi: 10.1016/j.bja.2019.07.026
Hirayama M, Ohno K (2021) Parkinson’s disease and gut microbiota. Ann Nutr Metab 77(Suppl 2):28–35
doi: 10.1159/000518147
Hong Y, Sheng L, Zhong J, Tao X, Zhu W, Ma J et al (2021) Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice. Gut Microbes 13:1–20
doi: 10.1080/19490976.2021.1930874
Hou R, Baldwin DS (2012) A neuroimmunological perspective on anxiety disorders. Hum Psychopharmacol 27:6–14
doi: 10.1002/hup.1259
Huang N, Hua D, Zhan G, Li S, Zhu B, Jiang R et al (2019) Role of Actinobacteria and Coriobacteriia in the antidepressant effects of ketamine in an inflammation model of depression. Pharmacol Biochem Behav 176:93–100
doi: 10.1016/j.pbb.2018.12.001
Jiang HY, Zhang X, Yu ZH, Zhang Z, Deng M, Zhao JH et al (2018) Altered gut microbiota profile in patients with generalized anxiety disorder. J Psychiatr Res 104:130–136
doi: 10.1016/j.jpsychires.2018.07.007
Jordan KD, Okifuji A (2011) Anxiety disorders: differential diagnosis and their relationship to chronic pain. J Pain Palliat Care Pharmacother 25:231–245
doi: 10.3109/15360288.2011.596922
Lach G, Schellekens H, Dinan TG, Cryan JF (2018) Anxiety, depression, and the microbiome: a role for gut peptides. Neurotherapeutics 15:36–59
doi: 10.1007/s13311-017-0585-0
Li M, van Esch B, Wagenaar GTM, Garssen J, Folkerts G, Henricks PAJ (2018) Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells. Eur J Pharmacol 831:52–59
doi: 10.1016/j.ejphar.2018.05.003
Lin H, Guo Q, Wen Z, Tan S, Chen J, Lin L et al (2021) The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors. Microb Cell Fact 20:233
doi: 10.1186/s12934-021-01720-1
Listos J, Talarek S, Fidecka S (2008) Adenosine receptor agonists attenuate the development of diazepam withdrawal-induced sensitization in mice. Eur J Pharmacol 588:72–77
doi: 10.1016/j.ejphar.2008.04.011
Liu RT, Walsh RFL, Sheehan AE (2019) Prebiotics and probiotics for depression and anxiety: a systematic review and meta-analysis of controlled clinical trials. Neurosci Biobehav Rev 102:13–23
doi: 10.1016/j.neubiorev.2019.03.023
Ma L, Li J, Zhou J, Zhang D, Xiao Z, Yu T et al (2021) Intravenous lidocaine alleviates postherpetic neuralgia in rats via regulation of neuroinflammation of microglia and astrocytes. iScience 24:102108
doi: 10.1016/j.isci.2021.102108
Noori Ahmad Abadi M, Mortazavi M, Kalani N, Marzouni HZ, Kooti W, Ali-Akbari S (2016) Effect of hydroalcoholic extract of Rosmarinus officinalis L leaf on anxiety in mice. J Evid Based Complementary Altern Med 21:Np85-90
doi: 10.1177/2156587216642101
Okoli AS, Wadstrom T, Mendz GL (2007) MiniReview: bioinformatic study of bile responses in Campylobacterales. FEMS Immunol Med Microbiol 49:101–123
doi: 10.1111/j.1574-695X.2006.00194.x
Parker BJ, Wearsch PA, Veloo ACM, Rodriguez-Palacios A (2020) The genus Alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health. Front Immunol 11:906
doi: 10.3389/fimmu.2020.00906
Scholz J, Woolf CJ (2002) Can we conquer pain? Nat Neurosci 5(Suppl):1062–1067
doi: 10.1038/nn942
Sharon G, Sampson TR, Geschwind DH, Mazmanian SK (2016) The central nervous system and the gut microbiome. Cell 167:915–932
doi: 10.1016/j.cell.2016.10.027
Shen S, Lim G, You Z, Ding W, Huang P, Ran C et al (2017) Gut microbiota is critical for the induction of chemotherapy-induced pain. Nat Neurosci 20:1213–1216
doi: 10.1038/nn.4606
Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L (2014) The role of short-chain fatty acids in health and disease. Adv Immunol 121:91–119
doi: 10.1016/B978-0-12-800100-4.00003-9
Teofani A, Marafini I, Laudisi F, Pietrucci D, Salvatori S, Unida V et al. (2022). Intestinal taxa abundance and diversity in inflammatory bowel disease patients: an analysis including covariates and confounders. Nutrients 14.
Ward BO, Stephens DN (1998) Sensitisation of withdrawal signs following repeated withdrawal from a benzodiazepine: differences between measures of anxiety and seizure sensitivity. Psychopharmacology 135:342–352
doi: 10.1007/s002130050521
Yang C, Fang X, Zhan G, Huang N, Li S, Bi J et al (2019) Key role of gut microbiota in anhedonia-like phenotype in rodents with neuropathic pain. Transl Psychiatry 9:57
doi: 10.1038/s41398-019-0379-8
Zhang JD, Liu J, Zhu SW, Fang Y, Wang B, Jia Q et al (2021a) Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation. Acta Pharmacol Sin 42:1821–1833
doi: 10.1038/s41401-020-00601-4
Zhang M, Hong Y, Wu W, Li N, Liu B, Sun J et al (2021b) Pivotal role of the gut microbiota in congenital insensitivity to pain with anhidrosis. Psychopharmacology 238:3131–3142
doi: 10.1007/s00213-021-05930-8
Zhuo M (2016) Neural mechanisms underlying anxiety-chronic pain interactions. Trends Neurosci 39:136–145
doi: 10.1016/j.tins.2016.01.006